Hims & Hers responds to FTC lawsuit
The company states the FTC disregarded evidence and will vigorously defend itself.
See the latest news and media coverage for Hims. We track all announcements, press releases, and industry mentions in real time, all in one place.
Men’s digital healthcare platform
hims.comLast updated
In short: Hims expanded its global footprint through acquisitions and launched GLP-1 weight-loss treatments while facing a lawsuit from the FTC.
The company states the FTC disregarded evidence and will vigorously defend itself.
The company outlines its transparency, data safeguards, and user choice tools.
Dr. Vinjamoori argues that banning peptides drives demand to unsafe gray markets and advocates for supervised compounding based on real-world evidence.
She will leave effective October 9, 2026, and serve as an advisor for the transition.
Hims & Hers operates a direct-to-consumer telehealth platform offering treatments across weight loss, sexual health, dermatology, mental health and other categories. The company generates revenue...
The FDA reported more than 1,700 adverse events involving compounded Semaglutide and Tirzepatide...
HIMS raised its 2026 revenue outlook after Q2 sales jumped 38.2%, but margin contraction and an $86.3 million net loss highlighted growth costs.
Hims faces an estimated $75,000 surcharge and must lower its dispute rate below 1.5%.
Track Hims and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Hims and other trending companies.